Regulatory News for October 2009

Novartis biological drug Ilaris approved in EU to treat children and adults with CAPS, a rare auto-inflammatory disease

The new biological medicine Ilaris® (canakinumab) has been approved in the EU to treat adults and children as young as four years old with CAPS, a rare life-long auto-inflammatory disease.
30 October, 2009

FDA approves new treatment for chronic lymphocytic leukaemia

The U.S. Food and Drug Administration has approved Arzerra (ofatumumab) for patients with chronic lymphocytic leukaemia, a slowly progressing cancer of the blood and bone marrow.
29 October, 2009

New medicine coding system to help address the growing risk of counterfeit medicines

The European Federation of Pharmaceutical Industries and Associations, the ‘voice of the research-based pharmaceutical industry in Europe’, today unveiled its pilot project to verify medicines and help reduce the risk of counterfeit medicines being dispensed to patients.
21 October, 2009

Regulatory News Archive

Novartis biological drug Ilaris approved in EU to treat children and adults with CAPS, a rare auto-inflammatory disease Novartis biological drug Ilaris approved in EU to treat children and adults with CAPS, a rare auto-inflammatory disease

FDA approves new treatment for chronic lymphocytic leukaemia FDA approves new treatment for chronic lymphocytic leukaemia

New medicine coding system to help address the growing risk of counterfeit medicines New medicine coding system to help address the growing risk of counterfeit medicines

Novartis biological drug Ilaris approved in EU to treat children and adults with CAPS, a rare auto-inflammatory disease

FDA approves new treatment for chronic lymphocytic leukaemia

New medicine coding system to help address the growing risk of counterfeit medicines